QIAGEN and AstraZeneca Enhance Partnership to Develop Companion Diagnostics for Chronic Diseases

Expanded Collaboration:
QIAGEN and AstraZeneca have expanded their partnership to develop companion diagnostics (CDx) for chronic diseases, moving beyond their previous focus on oncology.

QIAstat-Dx Platform:
QIAGEN will utilize its QIAstat-Dx system, a syndromic testing platform, to develop and validate a genotyping assay. This assay will enable fast decision-making for potential suitability for AstraZeneca’s genomically targeted medicines.

Precision Medicine:
The collaboration aims to advance precision medicine by tailoring treatments to the genetic profiles identified by companion diagnostics testing.

Expertise in CDx Development:
QIAGEN is a pioneer in precision medicine and has extensive experience in developing and commercializing companion diagnostics, with master collaboration agreements with over 30 global companies.

Chronic Disease Focus:
The partnership will focus on developing CDx for chronic diseases, leveraging QIAGEN’s expertise and AstraZeneca’s therapeutic pipeline.